Are GLP-1s a scam?

So is it a scam?

No — the drug is one of the better-evidenced things in modern medicine. But the question is not stupid, because a lot of what surrounds the drug earns the suspicion.

Start with what is not in dispute. Semaglutide and tirzepatide went through phase 3 randomised controlled trials, are approved by the FDA, EMA and MHRA, and have been prescribed as a drug class since 2005. The SELECT trial randomised 17,604 adults with cardiovascular disease and obesity and found major adverse cardiovascular events in 6.5% on semaglutide versus 8.0% on placebo over an average of 39.8 months. You do not run a trial that size and that long to sell a scam. Scams avoid endpoints.

So where does the suspicion come from? Four places, and each one is a legitimate grievance pointed at the wrong target.

"You gain it all back" — is that a scam?

It is a real and well-documented effect, and it was published by the manufacturer's own trial programme rather than uncovered by critics. In the STEP 1 trial extension, people who stopped semaglutide after 68 weeks regained roughly two-thirds of the weight they had lost over the following year, with cardiometabolic markers drifting back toward baseline.

That feels like a trap. It reads like a subscription with your body as the hostage. The more accurate framing is less satisfying but more useful: obesity behaves like a chronic condition, and this is what happens when you stop treating a chronic condition. Blood pressure rises when you stop antihypertensives too. Nobody calls that a scam because nobody was sold the idea that six months of ramipril was a cure.

Where the criticism does land: people were frequently not told this. If your prescriber described a course of treatment with an end date and never mentioned what the data says about stopping, that is a consent failure. It is just not evidence the molecule does not work.

Practically, the honest question before starting is "what is the plan at month eighteen" — and it has to be asked at month zero. We cover the off-ramp in the weight regain field guide.

The price problem is real and separate

List prices that run into four figures a month for a drug that costs a fraction of that to make will make anyone feel scammed, and that is a pricing and policy argument, not a scientific one.

The practical consequence matters more than the outrage: price is the single most common reason people stretch doses, split vials, buy from unverified sellers, or stop abruptly. Every one of those is a safety decision made for a financial reason, and it is the mechanism by which a pricing problem becomes a medical one.

If cost is what is pushing you, the productive move is naming it to your prescriber directly. Coverage criteria, formulary alternatives, patient assistance and a documented dose plan all exist. Improvised rationing does not have a safety profile. Our cost calculator works out the actual cost per pound so at least the trade-off is visible.

The grey market is where the actual fraud lives

If you want to find something in this category that genuinely deserves the word scam, it is the vial sold as a research chemical.

Products marketed "for research use only, not for human consumption" carry no requirement for identity, purity, sterility or potency testing. That disclaimer is not a formality — it is the entire legal basis for selling an injectable substance without proving what is in it. Nobody is verifying the dose on the label.

Regulators have been explicit here. The FDA has documented compounders using semaglutide sodium and semaglutide acetate — salt forms that are different chemical entities from the semaglutide in approved products and have not been shown to be safe or effective. It has warned that patients using compounded injectable semaglutide have administered five to twenty times the intended dose, largely because converting between milligrams, millilitres and syringe units is genuinely confusing. By early 2025 the agency had logged more than 455 adverse event reports linked to compounded semaglutide. In April 2026 it proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List.

Compounded is not automatically the same as grey market — a licensed pharmacy operating under a prescription is a different thing from a website shipping unlabelled vials. But the further from an approved product you go, the more of the safety evidence you leave behind, and none of it transfers by association.

Telehealth: good care and subscription traps look identical from outside

Some telehealth GLP-1 services are genuinely good medicine delivered efficiently. Others are subscription businesses with a prescriber attached. The difference is visible in specific behaviours, not in the website design.

The tell that outranks all the others: a service that will not tell you the exact product and concentration you are being sold, in writing, before you pay.

"Natural GLP-1" supplements

This is the one category on this page where "scam" is usually the correct word.

Products marketed as natural GLP-1 boosters, GLP-1 activators or plant-based Ozempic alternatives are not GLP-1 receptor agonists. Berberine is not "nature's Ozempic" — the comparison started as a social media line, not a finding. There is no supplement with trial evidence remotely comparable to semaglutide's, and the marketing borrows credibility from a drug it has no relationship to.

Some of these ingredients have modest, real effects on glucose metabolism. None of them do what a GLP-1 receptor agonist does, and buying one because it appeared next to the word Ozempic is the transaction the marketing is designed to produce.

The ninety-second red flag checklist

Before you buy anything, run this. Any single yes is worth stopping over.

• Sold as a research chemical or "not for human consumption."
• No prescription, no consultation, no medical history taken.
• The concentration is not stated before purchase, or the paperwork does not name the exact product.
• Marketed as containing semaglutide sodium or semaglutide acetate — different entities from approved semaglutide, not shown safe or effective.
• Guaranteed results, or a specific number of pounds promised.
• No named prescriber and no way to reach a clinician about a side effect.
• Payment in crypto, wire transfer, or anything with no chargeback route.
• Dose escalation happens automatically on a schedule, without anyone reviewing how you responded.
• The word "Ozempic" is used to sell something that is not semaglutide.
• Pressure tactics: countdown timers, expiring pricing, limited stock on a prescription medicine.

None of this makes the medication a scam. It makes the market around it one you have to navigate with your eyes open — which is a normal thing to have to do, and easier once you know what you are looking at.

Common questions

Are GLP-1 medications a scam?

No. Semaglutide and tirzepatide have phase 3 randomised trial evidence and approval from the FDA, EMA and MHRA, and the SELECT trial followed 17,604 people for a mean of 39.8 months. The suspicion usually attaches to pricing, to the grey market in unregulated vials, and to telehealth subscription models — which are real problems, but not the medication.

Is it a scam that you regain the weight after stopping?

The regain is real and documented — roughly two-thirds of lost weight within a year in the STEP 1 trial extension — but it was published by the trial programme itself, not hidden. It reflects obesity behaving as a chronic condition. The legitimate complaint is that many people were never told before starting.

Is compounded semaglutide legitimate?

It depends entirely on the source. A licensed compounding pharmacy filling a prescription is different from a website shipping research-chemical vials. The FDA has documented compounders using unapproved salt forms and has warned about patients injecting five to twenty times the intended dose. In April 2026 it proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List.

Do natural GLP-1 supplements work?

Not in any way comparable to GLP-1 receptor agonists. Products marketed as natural Ozempic alternatives, including berberine, are not GLP-1 receptor agonists and have no trial evidence approaching semaglutide's. The marketing borrows the drug's credibility.

How do I tell a good telehealth GLP-1 provider from a bad one?

Ask for the exact product name and concentration in writing before paying, check whether dose increases are reviewed by a clinician or applied automatically on a calendar, and confirm there is a route to a human when a side effect appears. A provider that will not name the product is the clearest single red flag.

Keep reading